Shareholding for the Period Ended June 30, 2016
Concord Drugs Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2016. For more details, kindly Click here19-07-2016
19-07-2016
Outcome of Board Meeting
Concord Drugs Ltd has informed BSE that the Board of Directors of the Company which was postponed from July 07, 2016 to July 16, 2016, 10.30 a.m., the following were duly considered and approved:1. Appointment of T. Narsimha Reddy as Additional Director and Managing Director of the Company.2. Appointment of S. Nagi Reddy as Chairman of the Company.16-07-2016
Board Meeting on July 07, 2016
Concord Drugs Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on July 07, 2016, inter alia, to consider the following:- Restructuring of the Board.30-06-2016
Standalone Financial Results for March 31, 2016
Concord Drugs Ltd has informed BSE about : 1. Standalone Financial Results for the period ended March 31, 201630-05-2016
Closure of Trading Window
Concord Drugs Ltd has informed BSE that the trading window in respect of the Company's Securities shall remain closed for all the Directors/Officers/Designed Employees of the Company from the trading hours on May 17, 2016 till close of the trading hours on June 01, 2016 as per the code of Internal Procedure and Conduct for Prevention of Insider Trading adopted by the Company for declaration of audited financial results for the quarter and year ended March 31, 2016.19-05-2016
Board Meeting Intimation for Results
Concord Drugs Ltd has informed BSE that the meeting of the Board of Directors of the Company will be held on May 30, 2016, inter alia, to consider the following:1. Audited financial results for the quarter and year ended 31.03.2016.2. Audit Report for the Quarter and Year ended 31.03.2016.3. Appointment of Secretarial auditor for the year 2016-17.19-05-2016
Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended March 31, 2016
Concord Drugs Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended March 31, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.21-04-2016
Shareholding for the Period Ended March 31, 2016
Concord Drugs Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2016. For more details, kindly Click here20-04-2016
Limited Review Report for December 31, 2015
Concord Drugs Ltd has informed BSE about : 1. Standalone Limited Review for the period ended December 31, 201522-02-2016